Jane Street’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-6,400
Closed -$207K 10574
2021
Q3
$207K Sell
6,400
-300
-4% -$9.96K ﹤0.01% 8788
2021
Q2
$205K Buy
+6,700
New +$194K ﹤0.01% 8778
2021
Q1
Sell
-12,200
Closed -$241K 9418
2020
Q4
$241K Buy
+12,200
New +$197K ﹤0.01% 6721
2020
Q3
Sell
-13,500
Closed -$153K 7642
2020
Q2
$153K Buy
+13,500
New +$192K ﹤0.01% 6537
2019
Q4
Sell
-9,100
Closed -$261K 5510
2019
Q3
$261K Sell
9,100
-2,400
-21% -$69.9K ﹤0.01% 4323
2019
Q2
$319K Buy
+11,500
New +$325K ﹤0.01% 4124

Other funds holding MYGN

Jane Street's MYGN Position: Q1 2026 in Review

Jane Street increased its Myriad Genetics (MYGN) stake by 2,110% in Q1 2026, buying an estimated $5.98M and bringing the position to 1,202,531 shares worth $5.41M. The position accounts for ﹤0.01% of the portfolio, ranked #3391.

Jane Street first reported a position in MYGN in Q4 2013 and has held it in 30 quarters since. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Jane Street held 1,202,531 shares of Myriad Genetics worth $5.41M as of Q1 2026.
  • Jane Street bought 1,148,114 Myriad Genetics shares in Q1 2026, an estimated $5.98M.
  • Myriad Genetics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3391 holding.
  • Jane Street first reported a position in Myriad Genetics in Q4 2013 and has held it in 30 quarters since.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.